Michael E Thase
Veterans Health Administration
6 Papers
4 Citations
Michael E Thase is an academic researcher from Veterans Health Administration. The author has contributed to research in topics: Major depressive disorder & Randomized controlled trial. The author has an hindex of 3, co-authored 6 publications. Previous affiliations of Michael E Thase include University of Alabama.
Chat about Author
Papers
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial.
Somaia Mohamed,Somaia Mohamed,Gary R. Johnson,Peijun Chen,Paul B. Hicks,Paul B. Hicks,Lori L. Davis,Lori L. Davis,Jean Yoon,Theresa Gleason,Julia E. Vertrees,Kimberly R. Weingart,Kimberly R. Weingart,Ilanit Tal,Alexandra Scrymgeour,David Lawrence,Beata Planeta,Michael E Thase,Grant D. Huang,Sidney Zisook,Sidney Zisook,Sanjai D. Rao,Sanjai D. Rao,Patricia Pilkinton,James Wilcox,Ali Iranmanesh,Mamta Sapra,George Jurjus,James P. Michalets,Muhammed Aslam,Thomas P. Beresford,Keith D. Anderson,Ronald Fernando,Sriram Ramaswamy,John Kasckow,Joseph Westermeyer,Gihyun Yoon,D. Cyril D’Souza,Gunnar Larson,William G. Anderson,Mary Klatt,Ayman Fareed,Shabnam I. Thompson,Carlos J. Carrera,Solomon S. Williams,Timothy M. Juergens,Lawrence J. Albers,Clifford S. Nasdahl,Gerardo Villarreal,Julia L. Winston,Cristobal A. Nogues,K. Ryan Connolly,Andre Tapp,Kari A. Jones,Gauri Khatkhate,Sheetal Marri,Trisha Suppes,Joseph M. LaMotte,Robin A. Hurley,Aimee R. Mayeda,Alexander B. Niculescu,Bernard A. Fischer,David Loreck,Nicholas Rosenlicht,Steven Lieske,Mitchell S. Finkel,John T. Little +66 more
TL;DR: Among a predominantly male population with major depressive disorder unresponsive to antidepressant treatment, augmentation with aripiprazole resulted in a statistically significant but only modestly increased likelihood of remission during 12 weeks of treatment compared with switching to bupropion monotherapy.
Addressing anhedonia to increase depression treatment engagement
TL;DR: The authors proposed interventions to improve treatment initiation and continuation by addressing deficits in each component of reward functioning, focusing on modifications of existing evidence-based interventions to meet the needs of individuals with heightened anhedonia.
22
Adding cognitive therapy to antidepressant medications decreases suicidal ideation.
TL;DR: Adding cognitive therapy to antidepressant medications may reduce suicidal ideation to a greater extent than medications alone, and combination treatment may be preferred for individuals with suicidal Ideation.
16
Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial
Somaia Mohamed,Gary R. Johnson,Varadan Sevilimedu,Sanjai D. Rao,Paul B. Hicks,Peijun Chen,Kimberly Lauro,George Jurjus,Patricia Pilkinton,Lori L. Davis,James Wilcox,Ali Iranmanesh,Mamta Sapra,Muhammad Aslam,James P. Michalets,Michael E Thase,Sidney Zisook,Csp# Vast-D Investigators +17 more
TL;DR: Although PTSD was associated with poorer overall outcomes, the presence of concurrent PTSD among Veterans in this trial did not affect the comparative effectiveness of medications on response, remission, or relapse after initial remission.
7
Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment-resistant major depressive disorder: A VAST-D report
Sidney Zisook,Sidney Zisook,Gary R. Johnson,Paul B. Hicks,Peijun Chen,Thomas P. Beresford,James P. Michalets,Sanjai Rao,Michael E Thase,James Wilcox,Varadan Sevilimedu,Somaia Mohamed +11 more
TL;DR: This secondary analysis of the VA Augmentation and Switching Treatments for Depression study compared the continuation phase treatment outcomes of three commonly used second‐step treatment strategies following at least one prior failed medication treatment attempt.
5